150 related articles for article (PubMed ID: 16545007)
1. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.
Rudy BJ; Lindsey JC; Flynn PM; Bosch RJ; Wilson CM; Hughes ME; Douglas SD;
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):213-21. PubMed ID: 16545007
[TBL] [Abstract][Full Text] [Related]
2. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
Flynn PM; Rudy BJ; Douglas SD; Lathey J; Spector SA; Martinez J; Silio M; Belzer M; Friedman L; D'Angelo L; McNamara J; Hodge J; Hughes MD; Lindsey JC;
J Infect Dis; 2004 Jul; 190(2):271-9. PubMed ID: 15216461
[TBL] [Abstract][Full Text] [Related]
3. Long-term observation of adolescents initiating HAART therapy: three-year follow-up.
Flynn PM; Rudy BJ; Lindsey JC; Douglas SD; Lathey J; Spector SA; Martinez J; Silio M; Belzer M; Friedman L; D'Angelo L; Smith E; Hodge J; Hughes MD;
AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1208-14. PubMed ID: 17961106
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
5. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
[TBL] [Abstract][Full Text] [Related]
7. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
8. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
9. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China.
Li X; Ding H; Geng W; Liu J; Jiang Y; Xu J; Zhang Z; Shang H
BMC Infect Dis; 2019 May; 19(1):373. PubMed ID: 31046702
[TBL] [Abstract][Full Text] [Related]
10. Defective IL-2 production by HIV-1-specific CD4 and CD8 T cells in an adolescent/young adult cohort.
Kapogiannis BG; Henderson SL; Nigam P; Sharma S; Chennareddi L; Herndon JG; Robinson HL; Amara RR
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):272-82. PubMed ID: 16545014
[TBL] [Abstract][Full Text] [Related]
11. Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.
Touloumi G; Paparizos V; Sambatakou H; Katsarou O; Chrysos G; Kordossis T; Antoniadou A; Hatzitheodorou H; Stavrianeas N; Gargalianos P; Karafoulidou A; Lazanas M; Giamarelou H; Hatzakis A
HIV Clin Trials; 2001; 2(1):6-16. PubMed ID: 11590509
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.
Vaamonde CM; Hoover DR; Anastos K; Tan T; Shi Q; Gao W; Kovacs A; Cohen M; DeHovitz J; Glesby MJ
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):222-31. PubMed ID: 16545008
[TBL] [Abstract][Full Text] [Related]
13. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
15. CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.
Scott-Algara D; Aboulker JP; Durier C; Badell E; Marcellin F; Prud'homme M; Jouanne C; Meiffredy V; Brun-Vezinet F; Pialoux G; Raffi F;
Clin Exp Immunol; 2001 Nov; 126(2):295-303. PubMed ID: 11703374
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.
Kaufmann GR; Zaunders JJ; Cunningham P; Cooper DA
AIDS Res Hum Retroviruses; 1999 Jul; 15(11):963-72. PubMed ID: 10445808
[TBL] [Abstract][Full Text] [Related]
17. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients.
Al-Harthi L; Voris J; Patterson BK; Becker S; Eron J; Smith KY; D'Amico R; Mildvan D; Snidow J; Pobiner B; Yau L; Landay A
HIV Med; 2004 Jan; 5(1):55-65. PubMed ID: 14731171
[TBL] [Abstract][Full Text] [Related]
19. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
Sterling TR; Chaisson RE; Keruly J; Moore RD
J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
[TBL] [Abstract][Full Text] [Related]
20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
